Christopher W. Helsen

784 total citations
16 papers, 652 citations indexed

About

Christopher W. Helsen is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Christopher W. Helsen has authored 16 papers receiving a total of 652 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Christopher W. Helsen's work include CAR-T cell therapy research (12 papers), Prion Diseases and Protein Misfolding (2 papers) and Immunotherapy and Immune Responses (2 papers). Christopher W. Helsen is often cited by papers focused on CAR-T cell therapy research (12 papers), Prion Diseases and Protein Misfolding (2 papers) and Immunotherapy and Immune Responses (2 papers). Christopher W. Helsen collaborates with scholars based in Canada, Poland and Germany. Christopher W. Helsen's co-authors include John R. Glover, Rainer Rudolph, Thomas Scheibel, Jonathan L. Bramson, Joanne A. Hammill, Galina Denisova, Johnny M. Tkach, Jennifer Bassett, Daniela Tantalo and Carole Evelegh and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Blood.

In The Last Decade

Christopher W. Helsen

16 papers receiving 635 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Christopher W. Helsen Canada	8	378	296	187	114	107	16	652
Benjamí Oller‐Salvia Spain	12	648 1.7×	244 0.8×	122 0.7×	133 1.2×	40 0.4×	27	975
Nina Kronqvist Sweden	16	779 2.1×	457 1.5×	84 0.4×	52 0.5×	72 0.7×	32	1.1k
Julien Ogier Ireland	16	525 1.4×	315 1.1×	27 0.1×	150 1.3×	48 0.4×	23	869
Quoc‐Viet Le South Korea	16	407 1.1×	198 0.7×	97 0.5×	415 3.6×	224 2.1×	33	884
Amy Winans United States	6	261 0.7×	112 0.4×	69 0.4×	113 1.0×	111 1.0×	11	505
Marco Herrera‐Barrera United States	9	605 1.6×	123 0.4×	28 0.1×	123 1.1×	75 0.7×	15	821
Carlos J. Bosques United States	15	537 1.4×	115 0.4×	26 0.1×	63 0.6×	139 1.3×	26	869
Kavitha S. Rao United States	13	363 1.0×	213 0.7×	29 0.2×	170 1.5×	27 0.3×	20	846
Meshkat Dinarvand Iran	16	561 1.5×	225 0.8×	46 0.2×	235 2.1×	81 0.8×	18	876

Countries citing papers authored by Christopher W. Helsen

Since Specialization

Citations

This map shows the geographic impact of Christopher W. Helsen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Christopher W. Helsen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Christopher W. Helsen more than expected).

Fields of papers citing papers by Christopher W. Helsen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Christopher W. Helsen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Christopher W. Helsen. The network helps show where Christopher W. Helsen may publish in the future.

Co-authorship network of co-authors of Christopher W. Helsen

This figure shows the co-authorship network connecting the top 25 collaborators of Christopher W. Helsen. A scholar is included among the top collaborators of Christopher W. Helsen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Christopher W. Helsen. Christopher W. Helsen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Benatar, Tania, et al.. (2025). Tuning TCR complex recruitment to the T cell antigen coupler (TAC) enhances TAC-T cell function. Scientific Reports. 15(1). 6769–6769. 1 indexed citations

Benatar, Tania, Suzanna L. Prosser, Alima Naim Khan, et al.. (2024). Preclinical Development of T Cells Engineered to Express a T-Cell Antigen Coupler Targeting Claudin 18.2–Positive Solid Tumors. Cancer Immunology Research. 13(1). 35–46. 2 indexed citations

Wang, Ling, Stacey X. Xu, Tania Benatar, et al.. (2023). Abstract 3188: Patient-derived TAC01-HER2 TAC T cells produced in Cocoon® Platform is highly functional in models of solid tumors. Cancer Research. 83(7_Supplement). 3188–3188. 1 indexed citations

Hammill, Joanne A., Derek T. Cummings, Bojana Bojović, et al.. (2023). T-cell engineered with a fully humanized B-cell maturation antigen-specific T-cell antigen coupler receptor effectively target multiple myeloma. Cytotherapy. 25(5). 490–501. 2 indexed citations

Wang, Ling, Stacey X. Xu, Tania Benatar, et al.. (2022). 294 Preclinical studies of TAC01-CLDN18.2, an autologous claudin 18.2-directed TAC T cell therapy, in the treatment of gastric cancer. Regular and Young Investigator Award Abstracts. A309–A309. 1 indexed citations

Helsen, Christopher W., et al.. (2019). Development of a CD19-TAC therapy in preparation of human trials. Cytotherapy. 21(5). S26–S26. 2 indexed citations

Helsen, Christopher W., Joanne A. Hammill, Vivian Wing Chong Lau, et al.. (2018). The chimeric TAC receptor co-opts the T cell receptor yielding robust anti-tumor activity without toxicity. Nature Communications. 9(1). 3049–3049. 106 indexed citations

Helsen, Christopher W., et al.. (2018). T Cells Engineered with T Cell Antigen Coupler (TAC) Receptors for Haematological Malignancies. Blood. 132(Supplement 1). 3267–3267. 2 indexed citations

Lau, Vivian Wing Chong, Galina Denisova, Carole Evelegh, et al.. (2018). T Cells Engineered with a Novel Chimeric Receptor Demonstrate Durable In Vivo Efficacy Against Disseminated Multiple Myeloma. Blood. 132(Supplement 1). 962–962. 2 indexed citations

10.

Hammill, Joanne A., et al.. (2016). Viral Engineering of Chimeric Antigen Receptor Expression on Murine and Human T Lymphocytes. Methods in molecular biology. 1458. 137–157. 9 indexed citations

11.

Helsen, Christopher W., et al.. (2016). Tumor-Targeting Domains for Chimeric Antigen Receptor T Cells. Immunotherapy. 9(1). 33–46. 8 indexed citations

12.

Hammill, Joanne A., Christopher W. Helsen, Galina Denisova, et al.. (2015). Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors. Journal for ImmunoTherapy of Cancer. 3(1). 55–55. 66 indexed citations

13.

Helsen, Christopher W. & John R. Glover. (2012). A new perspective on Hsp104-mediated propagation and curing of the yeast prion [PSI⁺]. Prion. 6(3). 234–239. 22 indexed citations

14.

Helsen, Christopher W. & John R. Glover. (2011). Insight into Molecular Basis of Curing of [PSI+] Prion by Overexpression of 104-kDa Heat Shock Protein (Hsp104). Journal of Biological Chemistry. 287(1). 542–556. 79 indexed citations

15.

Helsen, Christopher W., et al.. (2008). The C-terminal Extension of Saccharomyces cerevisiae Hsp104 Plays a Role in Oligomer Assembly. Biochemistry. 47(7). 1918–1927. 40 indexed citations

16.

Helsen, Christopher W., et al.. (2004). Primary Structure Elements of Spider Dragline Silks and Their Contribution to Protein Solubility. Biochemistry. 43(42). 13604–13612. 309 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact